Bradford D. Dahms - Net Worth and Insider Trading
Bradford D. Dahms Net Worth
The estimated net worth of Bradford D. Dahms is at least $24,937 dollars as of 2024-04-27. Bradford D. Dahms is the CFO of Theseus Pharmaceuticals Inc and owns about 6,142 shares of Theseus Pharmaceuticals Inc (THRX) stock worth over $24,937. Details can be seen in Bradford D. Dahms's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Bradford D. Dahms has not made any transactions after 2022-11-30 and currently still holds the listed stock(s).
Transaction Summary of Bradford D. Dahms
Bradford D. Dahms Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Bradford D. Dahms owns 2 companies in total, including Cartesian Therapeutics Inc (RNAC) , and Theseus Pharmaceuticals Inc (THRX) .
Click here to see the complete history of Bradford D. Dahms’s form 4 insider trades.
Insider Ownership Summary of Bradford D. Dahms
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RNAC | Cartesian Therapeutics Inc | 2020-07-01 | Chief Financial Officer |
| THRX | Theseus Pharmaceuticals Inc | 2022-11-30 | Chief Financial Officer |
Bradford D. Dahms Latest Holdings Summary
Bradford D. Dahms currently owns a total of 1 stock. Bradford D. Dahms owns 6,142 shares of Theseus Pharmaceuticals Inc (THRX) as of November 30, 2022, with a value of $24,937.
Latest Holdings of Bradford D. Dahms
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| THRX | Theseus Pharmaceuticals Inc | 2022-11-30 | 6,142 | 4.06 | 24,937 |
Holding Weightings of Bradford D. Dahms
Bradford D. Dahms Form 4 Trading Tracker
According to the SEC Form 4 filings, Bradford D. Dahms has made a total of 2 transactions in Theseus Pharmaceuticals Inc (THRX) over the past 5 years, including 2 buys and 0 sells. The most-recent trade in Theseus Pharmaceuticals Inc is the acquisition of 1,502 shares on November 30, 2022, which cost Bradford D. Dahms around $10,005.
Insider Trading History of Bradford D. Dahms
- 1
Bradford D. Dahms Trading Performance
GuruFocus tracks the stock performance after each of Bradford D. Dahms's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Bradford D. Dahms is 39.48%. GuruFocus also compares Bradford D. Dahms's trading performance to market benchmark return within the same time period. The performance of stocks bought by Bradford D. Dahms within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Bradford D. Dahms's insider trading performs compared to the benchmark.
Performance of Bradford D. Dahms
Average Return
-42.41%
Outperforming Transactions
0%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -9.8 | 39.48 | -12.85 | -42.41 | -37.59 | |
| Relative Return to S&P 500(%) | -4.15 | 42.71 | -4.88 | -40.1 | -38.63 |
Bradford D. Dahms Ownership Network
Ownership Network List of Bradford D. Dahms
Ownership Network Relation of Bradford D. Dahms
Bradford D. Dahms Owned Company Details
What does Cartesian Therapeutics Inc do?
Who are the key executives at Cartesian Therapeutics Inc?
Bradford D. Dahms is the Chief Financial Officer of Cartesian Therapeutics Inc. Other key executives at Cartesian Therapeutics Inc include Chief Medical Officer Peter G Traber , director & President & CEO Carsten Brunn , and Chief Scientific Officer Takashi Kei Kishimoto .
Cartesian Therapeutics Inc (RNAC) Insider Trades Summary
Over the past 18 months, Bradford D. Dahms made no insider transaction in Cartesian Therapeutics Inc (RNAC). Other recent insider transactions involving Cartesian Therapeutics Inc (RNAC) include a net purchase of 1,223,316 shares made by Timothy A Springer , a net sale of 48,524 shares made by Carsten Brunn , and a net sale of 12,349 shares made by Peter G Traber .
In summary, during the past 3 months, insiders sold 0 shares of Cartesian Therapeutics Inc (RNAC) in total and bought 40,777 shares, with a net purchase of 40,777 shares. During the past 18 months, 2,681 shares of Cartesian Therapeutics Inc (RNAC) were sold and 40,777 shares were bought by its insiders, resulting in a net purchase of 38,096 shares.
Cartesian Therapeutics Inc (RNAC)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cartesian Therapeutics Inc Insider Transactions
Bradford D. Dahms Mailing Address
Above is the net worth, insider trading, and ownership report for Bradford D. Dahms. You might contact Bradford D. Dahms via mailing address: C/o Selecta Biosciences, Inc., 480 Arsenal Way, Watertown Ma 02472.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
